Iranian Red Crescent Medical Journal

Published by: Kowsar

Occult HCV Infection: The Current State of Knowledge

Mohammad Saeid Rezaee-Zavareh 1 , 2 , Reza Hadi 2 , Hamidreza Karimi-Sari 1 , Mohammad Hossein Khosravi 1 , Reza Ajudani 1 , Fardin Dolatimehr 1 , Mahdi Ramezani-Binabaj 1 , Seyyed Mohammad Miri 2 , 3 and Seyed Moayed Alavian 2 , 4 , *
Authors Information
1 Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
3 Kowsar Medical Institute, Heerlen, The Netherlands
4 Baqiyatallah Research Center for Gasteroenterology and Liver Disease (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: November 01, 2015, 17 (11); e34181
  • Published Online: November 29, 2015
  • Article Type: Review Article
  • Received: October 30, 2015
  • Accepted: November 2, 2015
  • DOI: 10.5812/ircmj.34181

To Cite: Rezaee-Zavareh M S, Hadi R, Karimi-Sari H, Hossein Khosravi M, Ajudani R, et al. Occult HCV Infection: The Current State of Knowledge, Iran Red Crescent Med J. 2015 ; 17(11):e34181. doi: 10.5812/ircmj.34181.

Abstract
Copyright © 2015, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Definition and Diagnoses
2. Special Groups Need Special Attention
3. Immune Responses
4. Treatment
5. Analysis of Available Articles About OCI in Scopus
6. Conclusions
References
  • 1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345(1): 41-52[DOI][PubMed]
  • 2. Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN, et al. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol. 2011; 83(6): 989-95[DOI][PubMed]
  • 3. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012; 12 Suppl 2[DOI][PubMed]
  • 4. Jamali R. Epidemiologic Studies on Viral Hepatitis: A Short Review. Thrita. 2014; 3(1)
  • 5. Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004; 189(1): 7-14[DOI][PubMed]
  • 6. Rezaee Zavareh MS, Alavian SM, Karimisari H, Shafiei M, Saiedi Hosseini SY. Occult hepatitis C virus infection in patients with autoimmune hepatitis. Hepat Mon. 2014; 14(8)[DOI][PubMed]
  • 7. Bresters D, Cuypers HT, Reesink HW, Chamuleau RA, Schipper ME, Boeser-Nunnink BD, et al. Detection of hepatitis C viral RNA sequences in fresh and paraffin-embedded liver biopsy specimens of non-A, non-B hepatitis patients. J Hepatol. 1992; 15(3): 391-5[PubMed]
  • 8. Geller SA, Nichols WS, Rojter SE, Chan RCK, Petrovic LM, Vierling JM, et al. Hepatitis C virus is not recoverable from liver tissue in cryptogenic cirrhosis: Failure to identify hepatitis C virus-RNA using reverse transcription-mediated polymerase chain reaction. Hum Pathology. 1996; 27(11): 1161-5[DOI]
  • 9. Rezaee-Zavareh MS, Ramezani-Binabaj M, Moayed Alavian S. Screening for occult hepatitis C virus infection: Does it need special attention? Hepatology. 2015; 62(1): 321-2[DOI][PubMed]
  • 10. Castillo I, Bartolome J, Quiroga JA, Barril G, Carreno V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol. 2010; 82(9): 1554-9[DOI][PubMed]
  • 11. Quiroga JA, Castillo I, Pardo M, Rodriguez-Inigo E, Carreno V. Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection. J Clin Microbiol. 2006; 44(12): 4559-60[DOI][PubMed]
  • 12. Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann G, Petermann D, et al. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int. 1995; 48(6): 1967-71[PubMed]
  • 13. Carreno V, Castillo I, Bartolome J, Rodriguez-Inigo E, Ortiz-Movilla N, de Lucas S, et al. Comparison of hepatitis C virus RNA detection in plasma, whole blood and peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. J Clin Virol. 2004; 31(4): 312-3[DOI][PubMed]
  • 14. Bartolome J, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Quiroga JA, Palacios R, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol. 2007; 81(14): 7710-5[DOI][PubMed]
  • 15. Pardo M, Lopez-Alcorocho JM, Rodriguez-Inigo E, Castillo I, Carreno V. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J Viral Hepat. 2007; 14(1): 36-40[DOI][PubMed]
  • 16. Comar M, Dal Molin G, D'Agaro P, Croce SL, Tiribelli C, Campello C. HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J Clin Pathol. 2006; 59(5): 526-9[DOI][PubMed]
  • 17. Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S, et al. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon. 2013; 13(8)[DOI][PubMed]
  • 18. De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D, et al. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One. 2009; 4(12)[DOI][PubMed]
  • 19. Cortes-Mancera FM, Restrepo JC, Osorio G, Hoyos S, Correa G, Navas MC. Occult hepatitis C virus infection in a re-transplanted patient with liver failure of unknown etiology. Colomb J Gastroenterol. 2010; 25(1): 76-85
  • 20. Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM. Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat. 2012; 2012: 429784[DOI][PubMed]
  • 21. Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H. Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol. 2013; 85(2): 235-40[DOI][PubMed]
  • 22. Castillo I, Martinez-Ara J, Olea T, Bartolome J, Madero R, Hernandez E, et al. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int. 2014; 86(3): 619-24[DOI][PubMed]
  • 23. Prieto J, Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology. 1996; 23(2): 199-204[DOI][PubMed]
  • 24. Karlsberg PL, Lee WM, Casey DL, Cockerell CJ, Cruz PJ. Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia. Arch Dermatol. 1995; 131(10): 1119-23[PubMed]
  • 25. Walker NJ, Zurier RB. Liver abnormalities in rheumatic diseases. Clin Liver Dis. 2002; 6(4): 933-46[PubMed]
  • 26. Casato M, Lilli D, Donato G, Granata M, Conti V, Del Giudice G, et al. Occult hepatitis C virus infection in type II mixed cryoglobulinaemia. J Viral Hepat. 2003; 10(6): 455-9[PubMed]
  • 27. Parodi C, Culasso A, Aloisi N, Garcia G, Baston M, Corti M, et al. Evidence of occult HCV genotypes in haemophilic individuals with unapparent HCV mixed infections. Haemophilia. 2008; 14(4): 816-22[DOI][PubMed]
  • 28. Castillo I, Bartolome J, Quiroga JA, Carreno V. High prevalence of occult hepatitis C virus infection in patients with chronic hepatitis B virus infection. J Med Microbiol. 2013; 62: 1235-8[DOI][PubMed]
  • 29. Honarkar Z, Alavian SM, Samiee S, Saeedfar K, Zali MR. Occult hepatitis B among chronic liver disease patients. Saudi Med J. 2005; 26(4): 601-6[PubMed]
  • 30. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001; 33(2): 455-63[DOI][PubMed]
  • 31. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology. 2009; 49(2): 665-75[DOI][PubMed]
  • 32. Kodali VP, Gordon SC, Silverman AL, McCray DG. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. Am J Gastroenterol. 1994; 89(10): 1836-9[PubMed]
  • 33. Verslype C, Nevens F, Sinelli N, Clarysse C, Pirenne J, Depla E, et al. Hepatic immunohistochemical staining with a monoclonal antibody against HCV-E2 to evaluate antiviral therapy and reinfection of liver grafts in hepatitis C viral infection. J Hepatol. 2003; 38(2): 208-14[PubMed]
  • 34. Halfon P, Bourliere M, Ouzan D, Sene D, Saadoun D, Khiri H, et al. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol. 2008; 46(6): 2106-8[DOI][PubMed]
  • 35. Zaghloul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest. 2010; 39(3): 284-91[DOI][PubMed]
  • 36. Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H, et al. Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol. 2011; 11(2): 442-5[DOI][PubMed]
  • 37. Makvandi M, Khalafkhany D, Rasti M, Neisi N, Omidvarinia A, Mirghaed AT, et al. Detection of Hepatitis C virus RNA in peripheral blood mononuclear cells of patients with abnormal alanine transaminase in Ahvaz. Indian J Med Microbiol. 2014; 32(3): 251-5[DOI][PubMed]
  • 38. Rostami Z, Lessan Pezeshki M, Soleimani Najaf Abadi A, Einollahi B. Health Related Quality of Life in Iranian Hemodialysis Patients With Viral Hepatitis: Changing Epidemiology. Hepat Mon. 2013; 13(6)[DOI][PubMed]
  • 39. Hooda A, Varma P, Chopra G, Kaur J. High prevalence of hepatitis C virus-ribonucleic acid positivity in anti-hepatitis C virus negative renal transplant patients. Med J Armed Forces India. 2012; 68(2): 123-8[DOI][PubMed]
  • 40. Nicot F, Kamar N, Mariame B, Rostaing L, Pasquier C, Izopet J. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int. 2010; 23(6): 594-601[DOI][PubMed]
  • 41. Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D, et al. Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol. 2008; 80(5): 808-15[DOI][PubMed]
  • 42. Baid-Agrawal S, Schindler R, Reinke P, Staedtler A, Rimpler S, Malik B, et al. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol. 2014; 60(5): 928-33[DOI][PubMed]
  • 43. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol. 2008; 19(12): 2288-92[DOI][PubMed]
  • 44. Jain P, Nijhawan S. Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients. World J Gastroenterol. 2008; 14(14): 2288-9[PubMed]
  • 45. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail. 2006; 28(8): 729-35[DOI][PubMed]
  • 46. Eslamifar A, Ramezani A, Ehteram H, Razeghi E, Ahmadi F, Amini M, et al. Occult hepatitis C virus infection in Iranian hemodialysis patients. J Nephropathol. 2015; 4(4): 116-20[DOI][PubMed]
  • 47. Sugden PB, Pham TN, Ratnarajah S, Cameron B, Bull R, White PA, et al. Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a two-centre, masked, case-control study. J Viral Hepat. 2013; 20(10): 725-8[DOI][PubMed]
  • 48. Sugden PB, Cameron B, Bull R, White PA, Lloyd AR. Occult infection with hepatitis C virus: friend or foe? Immunol Cell Biol. 2012; 90(8): 763-73[DOI][PubMed]
  • 49. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004; 189(10): 1846-55[DOI][PubMed]
  • 50. Rai RR, Mathur A, Mathur D, Udawat HP, Nepalia S, Nijhawan S. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission. Trop gastroenterol (official journal of the Digestive Diseases Foundation). 2006; 28(1): 19-23
  • 51. Pisaturo M, Guastafierro S, Filippini P, Tonziello G, Sica A, Di Martino F, et al. Absence of occult HCV infection in patients experiencing an immunodepression condition. Infez Med. 2013; 21(4): 296-301[PubMed]
  • 52. Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T. Occurrence of occult HCV infection among Hiv infected patients in Georgia. Georgian Med News. 2014; (226): 37-41[PubMed]
  • 53. El Shazly Y, Hemida K, Rafik M, Al Swaff R, Ali-Eldin ZA, GadAllah S. Detection of occult hepatitis C virus among healthy spouses of patients with HCV infection. J Med Virol. 2015; 87(3): 424-7[DOI][PubMed]
  • 54. Castillo I, Bartolome J, Quiroga JA, Barril G, Carreno V. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. J Med Virol. 2009; 81(7): 1198-203[DOI][PubMed]
  • 55. De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C, et al. Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS One. 2012; 7(8)[DOI][PubMed]
  • 56. Ashrafi Hafez A, Baharlou R, Mousavi Nasab SD, Ahmadi Vasmehjani A, Shayestehpour M, Joharinia N, et al. Molecular epidemiology of different hepatitis C genotypes in serum and peripheral blood mononuclear cells in jahrom city of iran. Hepat Mon. 2014; 14(5)[DOI][PubMed]
  • 57. Hartleb M, Gutkowski K, Zejda JE, Chudek J, Wiecek A. Serological prevalence of hepatitis B virus and hepatitis C virus infection in the elderly population: Polish nationwide survey–PolSenior. Euro j gastroenterol hepatol. 2012; 24(11): 1288-95[DOI]
  • 58. Nagao Y, Kawahigashi Y, Sata M. Association of Periodontal Diseases and Liver Fibrosis in Patients With HCV and/or HBV infection. Hepat Mon. 2014; 14(12)[DOI][PubMed]
  • 59. Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Pardo M, Carreno V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol. 2006; 80(22): 10972-9[DOI][PubMed]
  • 60. Pham TN, Mercer SE, Michalak TI. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat. 2009; 16(8): 547-56[DOI][PubMed]
  • 61. Tsuda N, Yuki N, Mochizuki K, Nagaoka T, Yamashiro M, Omura M, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol. 2004; 74(3): 406-13[DOI][PubMed]
  • 62. Besharat S, Katoonizadeh A, Moradi A. Potential mutations associated with occult hepatitis B virus status. Hepat Mon. 2014; 14(5)[DOI][PubMed]
  • 63. Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat. 2012; 19(2): 103-11[DOI][PubMed]
  • 64. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008; 134(3): 812-22[DOI][PubMed]
  • 65. Castillo I, Rodriguez-Inigo E, Bartolome J, de Lucas S, Ortiz-Movilla N, Lopez-Alcorocho JM, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut. 2005; 54(5): 682-5[DOI][PubMed]
  • 66. Carreno V, Bartolome J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol. 2012; 18(23): 2887-94[DOI][PubMed]
  • 67. Castillo I, Bartolome J, Quiroga JA, Barril G, Carreno V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int. 2011; 31(10): 1519-24[DOI][PubMed]
  • 68. Pham TN, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int. 2010; 30(4): 502-11[DOI][PubMed]
  • 69. Roque‐Cuellar MC, Sanchez B, García‐Lozano JR, Praena‐Fernandez JM, Márquez‐Galan JL, Núñez‐Roldan A, et al. Hepatitis C virus‐specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells. Liver Int. 2014; 34(6)-8
  • 70. Gad YZ, Ahmad NA, Mousa N, Farag RE, Abdel-Aziz AA, Abousmra NM, et al. Occult hepatitis C infection: the prevalence and profile of its immunoregulatory cytokines. Egypt Liver J. 2012; 2(4): 108-12[DOI][PubMed]
  • 71. Mousa N, Eldars W, Eldegla H, Fouda O, Gad Y, Abousamra N, et al. Cytokine profiles and hepatic injury in occult hepatitis C versus chronic hepatitis C virus infection. Int J Immunopathol Pharmacol. 2014; 27(1): 87-96[PubMed]
  • 72. Carreno V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol. 2006; 12(43): 6922-5[PubMed]
  • 73. Quiroga JA, Castillo I, Bartolome J, Carreno V. Serum immunoglobulin G antibodies to the GOR autoepitope are present in patients with occult hepatitis C virus (HCV) infection despite lack of HCV-specific antibodies. Clin Vaccine Immunol. 2007; 14(10): 1302-6[DOI][PubMed]
  • 74. Quiroga JA, Castillo I, Llorente S, Bartolome J, Barril G, Carreno V. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. J Hepatol. 2009; 50(2): 256-63[DOI][PubMed]
  • 75. Pardo M, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Perez-Mota A, Carreno V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther. 2006; 23(8): 1153-9[DOI][PubMed]
  • 76. Rezaee-Zavareh MS, Einollahi B. Treatment of occult hepatitis C virus infection: does it need special attention? Hepat Mon. 2014; 14(7)[DOI][PubMed]
  • 77. Alavian SM. Sofosbuvir has come out of the magic box. Hepat Mon. 2013; 13(12)[DOI][PubMed]
  • 78. Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients? Hepat Mon. 2014; 14(11)[DOI][PubMed]
  • 79. Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther. 2014; 12(7): 763-73[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments